Kornimate/medical-research-clean huggingface dataset:
the effect of cortisol administration on neural correlates of emotion in depression

Conditions: Depression

Summary: there is good evidence to suggest that the pathological version of sadness that people with major depression experience could be caused by the failure of the hormone cortisol to properly inhibit sadness-related brain activity in the subgenual cingulate cortex. this project investigates if the subgenual cingulate cortex has become insensitive to cortisol in patients with depression and tests for variants of the cortisol receptor genes that could predispose individuals to develop cortisol insensitivity.


Eligibility criteria:
https://redcap.stanford.edu/surveys/?s=3f7wcenpnd inclusion criteria: * healthy participants must have no axis 1 mental disorder * participants with depression must meet minimum severity levels (hamilton \>7) * all participants must weight less than 280 pounds for the purposes of mri scanning exclusion criteria: in order to protect against risk associated with taking hydrocortisone, all participants must not have any of the following: * psychotropic medications * recent surgery * endocrine disorders * liver disease * kidney disease * thyroid disorder * history of malaria * tuberculosis * osteoporosis * glaucoma/cataracts * chronic expressed infections (herpes --including ocular herpes, hiv, etc.) * history of congestive heart failure * history of recurring seizures * stomach ulcers * comorbid psychosis * current use of illicit drugs * high blood pressure in order to protect against risks associated with mri scanning participants must not be/have any of the following: * \>280 lbs * in-dwelling ferrous metals * left handed * abnormal hearing * claustrophobic * head injury with loss of consciousness

Keywords: depression cortisol sadness genetics stress
surgical activity during the covid-19 pandemic: results for 112 patients in a french tertiary care center

Conditions: Digestive Cancer; Gynaecological Cancer; Head and Neck Cancer

Summary: background after the emergence of covid-19 in china, hubei province, the epidemic quickly spread to europe. france was quickly hit and the croix-rousse hospital at the hospices civils de lyon was one of the first french university hospital to receive patients infected with sars-cov2. the predicted massive influx of patients motivated the cancellation of all elective surgical procedures planned to free hospitalization beds and to free intensive care beds. nevertheless, patients who had to be canceled had to be properly selected to avoid a life threatening. the retained surgical indications were surgical emergencies, oncologic surgery and organ transplantation. the objective was to describe the organization of the croix-rousse hospital to allow the continuation of these surgical activities while limiting the exposure of patients to the sars cov2.


Eligibility criteria:
inclusion criteria: * surgical management * \> 18 years old exclusion criteria: * \< 18 years old
an extension study for treatment of moderately to severely active ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this open-label extension (ole) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (uc) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified phase 3 or phase 2 double-blind, placebo-controlled parent studies including but not limited to: (apd334-301 \[nct03945188\] or apd334-302 \[nct03996369\] or apd334-210 \[nct04607837\]).


Eligibility criteria:
inclusion criteria: * must have met the eligibility criteria and have been enrolled in the qualified phase 2 or 3 parent studies listed below or other qualified region-specific studies and meet the following additional criteria: 1. participants previously enrolled in study apd334-301 (nct03945188) or apd334-210 (nct04607837) must have completed the week 12 visit and have been assessed to have active uc that has not improved or has worsened from baseline or completed the week 52 visit 2. participants previously enrolled in apd334-302 (nct03996369) must have completed the week 12 visit exclusion criteria: * if investigator considers the participant to be unsuitable for any reason to participate in the open-label extension study * experienced an adverse event that led to discontinuation from parent study

Keywords: ulcerative colitis etrasimod apd334
evaluation in elderly individuals with chronic obstructive pulmonary disease(copd)

Conditions: COPD (Chronic Obstructive Pulmonary Disease)

Summary: this study is conducted on the evaluation of balance, physical activity, functional capacity and activities of daily living in frail elderly individuals with copd.

patient evaluation form and socio-demographic form of all individuals participating in the study. characteristics will be questioned: name-surname, address, telephone, age, gender, weight, height, body mass index, occupation, marital status, social security, any systemic other than copd whether he has a disease, whether he has social security, whether he smokes, it will be questioned whether there is any other copd patient in the family and whether there is pain. to assess pulmonary functions at the assessment stage for all individuals pulmonary function test to evaluate dyspnea modified medical saint george respiratory research council to assess health-related quality of life two minute walk test to assess exercise capacity, frailty frail fragility scale to detect frailty, prisma-7 vulnerability scale to assess fragility the scale was pase to assess physical activity, berg balance to assess balance scale, digital hand dynamometer to assess quadriceps muscle strength, hand grip hand dynamometer to assess strength, fatigue levels fatigue severity scale will be used to evaluate.

Eligibility criteria:
inclusion criteria: * being diagnosed with copd according to the gold criteria * be over 65 years old * volunteering to participate in the study * not having mental and communication problems that prevent filling out the questionnaires to be used in the research. * not having an attack in the last 2 months exclusion criteria: * being in a copd exacerbation process * having been diagnosed with a physical and mental illness * having unstable copd * unstabile angina, previous myocardial infractus, uncontrolled hypertension, cancer, with functional limitations concomitant neurological or musculoskeletal disorders * currently addicted to alcohol or drugs * having severe vision and hearing problems * have had major surgery in the last few months * history of recurrent significant clinical infection

Keywords: copd (chronic obstructive pulmonary disease) fragility geriatric
patient satisfaction and safety outcomes after enrollment in a same-day (sd) percutaneous coronary intervention program

Conditions: To Evaluate Clinical Outcomes, Safety, and Satisfaction of Patients Who Have Participated in a Same Day Outpatient Percutaneous Coronary Artery Intervention

Summary: subjects in this study have recently had or are scheduled for a (percutaneous coronary intervention) pci as part of their normal, routine medical care. this procedure should restore the blood flow in the vessels of the heart. recent studies have shown that stable patients who undergo pci and are discharged home after 4 hours of observation do not suffer any more complications compared to patients who stay in the hospital overnight. in addition, studies suggest that patients express increased satisfaction at being discharged after 4 hours. the university of chicago is one of the first us medical centers to institute a formal program of same-day discharge after pci. this study will seek, through a analysis of medical information and satisfaction questionnaires, to assess whether this particular same-day discharge program can improve patient satisfaction and preserve patient safety.


Eligibility criteria:
inclusion criteria: * age 18 and up * undergoes coronary angiography in the cardiac catheterization laboratory exclusion criteria: * if the subject declines participation

Keywords: percutaneous coronary artery intervention coronary disease
composites and urinary bisphenol-a study

Conditions: Dental Caries

Summary: the composites and urinary bisphenol-a study (cubs) is a clinical study of dental composite for its effects on urinary bisphenol-a levels. the study will enroll approximately 139 children recruited from study-affiliated clinical sites in new england.the primary aim of cubs is to test the hypothesis that urinary bisphenol-a (bpa) concentrations increase after composite restoration placement. bpa is a chemical used in the synthesis of matrix monomers and has been shown to have harmful effects in toxicological studies in laboratory animals. currently it is unknown whether dental composite restorative materials containing monomers that are derived from bpa result in chronic low-dose bpa exposure in children.

study subjects will be new or existing patients of the clinical sites who are in need of dental restorations, meet all eligibility criteria, and provide informed consent/assent to participate. subjects will be asked to provide two pre-treatment urine samples and three post-treatment samples. urine collections occur next-day and 14 days after treatment, with one final urine collected approximately 6 months later (marking the end of the subject's active study participation). data will be collected from the clinician's standard oral examination (including new and existing dental treatments), the data collector's measurements of height and weight and interviews administered to the parents/guardians to assess sociodemographic and other relevant factors (e.g., recent food/beverage consumption). confidentiality will be maintained by assigning each subject a unique number and using only this number or aggregate data in all study reports. all study records will be securely maintained with access limited to essential study personnel only.

Eligibility criteria:
inclusion criteria: * aged 3-16 (\<17) years at enrollment. * 2+ posterior teeth with caries requiring restorations treatable by composite. * toilet-trained (not using diapers, pull-ups, or training pants during day or night). exclusion criteria: * medical conditions that would render the subject physically unable to provide urine samples. * guardian is not proficient in spoken english or spanish language * child is aged 8.0 years or older and not proficient in spoken english or spanish language * living \>35 miles outside of the dental clinic or the neri office (watertown ma)

Keywords: dental caries dental restorative materials dental composite bisphenol-a
a study to evaluate the dose-related efficacy and safety of ps433540 in subjects with hypertension

Conditions: Hypertension

Summary: the purpose of this study is to learn which doses of ps433540 should be given to patients with high blood pressure to lower their blood pressure. this study will also examine how safe ps433540 is when taken by patients with high blood pressure. approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given ps433540.


Eligibility criteria:
inclusion criteria: * males or females 18 - 70 years * mean seated systolic blood pressure (sbp) ≥ 140 mmhg and \ 90 and \< 109 mmhg at two consecutive qualifying visits (visits 3/3.5 and visit 4). the mean difference in dbp between the two consecutive qualifying visits must be ≤ 10 mmhg. * women of child-bearing potential (wocbp) must use two reliable forms of contraception if sexually active. alternatively, female subjects must be postmenopausal (for at least 1 year). exclusion criteria: * subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of ps433540, including cardiovascular (includes subjects who are known to have coronary artery disease), renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic, hematologic, neurologic and psychiatric diseases. * history of malignancy other than adequately treated basal cell or squamous cell skin cancer. * subjects with a history of myocardial infarction or new york heart association (nyha) class ii-iv heart failure. * subjects with a history of cerebrovascular accident or transient ischemic attack. * subjects with clinically significant cardiac conduction defects, including second or third degree atrioventricular block (av block), left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication. * subjects with hemodynamically significant valvular disease. * subjects with history of type 1 diabetes mellitus and subjects with a history of type 2 diabetes mellitus using antihyperglycemic medication (oral medication, insulin, or exenatide) are excluded.

Keywords: hypertension high blood pressure
study evaluating the efficacy of administration of cyclosporine (low dose and high dose) and prednisolone acetate compared to its components and vehicle in patients with allergic conjunctivitis

Conditions: Allergic Conjunctivitis

Summary: the purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * history of ocular allergies and a positive skin test reaction to perennial allergens within the past 24 months and a history of chronic eye irritation * visual acuity score ≥ 0.60 (edts) * negative urine pregnancy test for female patients, and use of adequate birth control throughout the study period. exclusion criteria: * active ocular infection; preauricular lymphadenopathy or ocular condition that could affect study; glaucoma or abnormal intraocular pressure; ocular surgery within past 3 months; history of asthma, pregnancy or nursing * contraindications or known allergies to the study drug(s)
randomized phase ii trial of salvage radiotherapy for prostate cancer in 4 weeks v. 2 weeks

Conditions: Prostate Cancer

Summary: the purpose of this study is to compare urinary and bowel side effects of hypofractionated radiotherapy in 20 treatments (4 weeks) to ultra-hypofractionated radiotherapy in 5 treatments (2 weeks) for prostate cancer that has returned after prostatectomy. the investigators are also interested in looking at time to progression and the quality of life (health scores).

the standard treatment for most patients with biochemical recurrence after radical prostatectomy is salvage radiotherapy. salvage radiotherapy delays the need for chronic, non-curative treatment, such as long-term androgen suppression, and is the only potentially curative treatment of some biochemical recurrences after prostatectomy. patients are recommended to undergo salvage radiotherapy to eradicate biochemical disease delivered in approximately 40 treatments over the course of 8 weeks, representing a high burden of therapy, which may be related to lower utilization of salvage radiotherapy. modern radiotherapy for prostate cancer has been afforded many advantages including advanced image-guided radiotherapy allowing for larger dose delivery in fewer treatments and smaller margins with hypofractionated (20 treatments) and ultra-hypofractionated (5 treatments) radiotherapy. in patients that need salvage radiotherapy, the potential advantages of hypofractionated and ultra-hypofractionated radiotherapy delivered over 20 or 5 treatments are: 1) increased convenience to patients because of fewer treatment days, 2) reduced costs to patients because of reduced travel expenses and copays, 3) improved resource utilization for physicians because of the fewer number of treatments per patient and consequently 4) reduced cost to society. in prostate cancer specifically, hypofractionated and ultra-hypofractionated radiotherapy has the added potential of not increasing toxicity with shorter treatment times.

Eligibility criteria:
inclusion criteria: * men aged 18 and older with histologically confirmed prostate cancer after prostatectomy with detectable psa. psa does not need to be detectable for men with pathologically node positive disease. * kps \>=70 * patient with no evidence of distant metastatic disease on pet/ct/mri or bone scan \< 9 months prior to enrollment. patients with positive pelvic lymph nodes are eligible. * ability to receive mri-guided radiotherapy. * equivocal evidence of metastatic disease outside the pelvis on standard imaging requires documented negative biopsy. * ability to complete the expanded prostate cancer index composite (epic) questionnaire. exclusion criteria: * prior history of receiving pelvic radiotherapy. * patient with inflammatory bowel disease. * patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of ultra-hypofractionated radiotherapy. * history of bladder neck or urethral stricture.
supervised endurance training among pulmonary arterial hypertension patients

Conditions: Pulmonary Arterial Hypertension

Summary: to compare the effects of supervised endurance training versus home based exercise plan on functional capacity and fatigue among pulmonary arterial hypertension patients.


Eligibility criteria:
inclusion criteria: * patients with pulmonary arterial hypertension, not pregnant and tobacco free. * age = 21 to 82 * patients with documented pah diagnosed by echocardiography (enlarged ra an enlarged rv with a thick wall, septal shift by enlarged chambers of right side of heart, an elevated mpap) or a resting mean pulmonary arterial pressure equal to 25mm hg determined by right heart catheterization. * patients on stable ph therapies, sedentary, and had no pulmonary rehabilitation for 6 months prior to enrolment. exclusion criteria: * patients will be excluded if they are not able to complete 6mwt. * a documented pulmonary capillary wedge pressure greater then or equal to 15 mm hg. * significant hepatic, renal, metabolic or mitochondrial dysfunctions; severe psychiatric disease; use of beta-adrenergic blockers or antiretroviral therapies; and any musculoskeletal or neurological condition that would limit walking or exercise performance. * patients with a history of heart failure.
dual frequency stimulation in parkinson's disease

Conditions: Parkinson Disease

Summary: deep brain stimulation (dbs) in the dorsal region of the subthalamic nucleus (stn) is very effective for reducing motor symptoms of parkinson's disease (pd). modeling studies suggest that this therapy may result in current spread into the ventral stn, causing altered cognitive processes. as a result, current stimulation parameters often lead to worsening in verbal fluency, executive function, and, particularly, cognitive control. there is evidence suggesting that low frequency oscillatory activity occurs across brain circuits important in integrating information for cognition. preclinical studies and human recording studies indicate these low frequency theta oscillations drive cognitive control during cognitive tasks. thus, the purpose of this study is to determine the safety, tolerability, and efficacy of low frequency stimulation (lfs) of the ventral stn alongside standard high frequency stimulation (hfs) of the dorsal stn in patients with pd.


Eligibility criteria:
inclusion criteria: * individuals who are 18 years and older * individuals with idiopathic parkinson's disease who previously underwent implantation with the boston scientific vercisetm dbs system * individuals who have been implanted with the boston scientific vercisetm dbs system for at least 3 months * individuals diagnosed with advanced pd who had bilateral dorsal subthalamic nucleus dbs surgery, as standard of care for motor improvement, with distal contacts of the electrodes implanted into the ventral stn exclusion criteria: * individuals unable to provide consent and/or lack capacity to consent * individuals diagnosed with any cognitive or physical impairments that would limit their ability to participate in the cognitive testing * individuals who score below 15 on the montreal cognitive assessment test-blind * individuals who score above 20 on the center for epidemiologic studies depression scale * pregnant women (note: pregnant women are not candidates for dbs surgery), and prisoners * non-english speaking individuals. cognitive tasks will only be conducted in english.

Keywords: dbs deep brain stimulation stn subthalamic nucleus parkinson disease dual frequency dual region dfdr
endometriosis and frequency of endometriosis-associated ovarian carcinomas (eaoc)

Conditions: Endometrioid Carcinoma; Clear Cell Carcinoma; Endometriosis

Summary: the purpose of this study is to determine whether a relationship exists between a previously established diagnosis of endometriosis and the consecutive risk of developing a clear cell or endometrioid ovarian carcinoma. all histopathological records since 1980 with these diagnoses (endometriosis, clear cell and endometrioid ovarian carcinoma) will be reviewed. cancer registry data will be assessed to investigate differences in survival of women with endometriosis-associated ovarian carcinomas and those ovarian carcinoma patients without previous diagnosis of endometriosis.


Eligibility criteria:
inclusion criteria: * endometrioid ovarian carcinoma * clear cell ovarian carcinoma * endometriosis, atypical endometriosis * borderline tumors with endometriosis exclusion criteria: * undifferentiated carcinomas * germ cell tumors * sex cord-stromal tumors
epidural versus wound infusion plus morphine bolus in open abdominal aortic aneurysm repair

Conditions: Postoperative Pain

Summary: the aim of the study is to determine wether continuous wound infusion with local anaesthetic plus a single dose intravenous morphine is non-inferior to postoperative analgesia provided with continuous thoracic epidural infusion of local anaesthetic plus opiate, in patients undergoing open abdominal aortic aneurism repair.


Eligibility criteria:
inclusion criteria: * scheduled for elective open aortic aneurism repair exclusion criteria: * patient refusal * platelet count \< 80\*10\^3/mcl * international normalised ratio \> 1.5 * other contraindications to the placement of epidural catheter, including ongoing anti platelet or anticoagulant treatment not suspended according to national guidelines
a study of the effect of time-of-day of training on chronic patellar tendinopathy

Conditions: Tendinopathy; Jumper's Knee

Summary: the study is a 12-week human study where 60 participants with chronic patellar tendinopathy (more than 3 months symptoms duration) are randomised to undergo 12 weeks of targeted resistance exercise either in the morning or in the late afternoon. the overall aim is to investigate when the best time of the day to perform muscular strength training therapy towards tendinopathy is. the study will also include 10 healthy controls who will not perform any exercise training.


Eligibility criteria:
inclusion criteria: * sports active men and women * age (18-55) years old * bmi (18.5-30) * uni- or bilateral patellar tendinopathy * symptom onset \>90 days ago exclusion criteria: * patellar tendinopathy longer than 24 months * previous surgery in the knee on the ipsilateral side * corticosteroid injection in the patellar tendon on the ipsilateral side within the last 6 months * any confounding diagnosis to the knee joint * known arthritis * known diabetes * known rheumatic disorders * inability to follow rehabilitation or complete follow-ups * enrolled in a resistance based-rehabilitation program for the affected patellar tendon within the previous 3 months * have an occupation where it is not feasible to avoid pain provoking tasks * pregnancy * have sleeping disorders or disruptions, e.g., night shift work * use of medicines or supplements known to affect collagen synthesis or sleep